Aclaris Therapeutics, Inc. ACRS
ACRS Rating
ACRS Rating Factors
ACRS Company Overview
Aclaris Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing immuno-inflammatory therapies and specialty dermatology treatments. The company operates primarily in the biotechnology and pharmaceutical industries, with an emphasis on small-molecule and kinase inhibitor therapies targeting immune-mediated diseases. Historically, Aclaris generated revenue from commercial dermatology products, but in recent years it has shifted toward a development-stage biotechnology model centered on immunology and inflammation-focused drug candidates.
The company’s primary business lines include research and development of oral and topical therapeutics, particularly kinase inhibitors targeting pathways associated with inflammatory and autoimmune conditions. Aclaris has pursued indications in dermatology, rheumatology, and immunology, including alopecia areata and atopic dermatitis. The company was founded in 2012 and expanded initially through acquisitions and commercialization of dermatology products before restructuring its portfolio to prioritize pipeline development and strategic partnerships. Its positioning has been supported by internal drug discovery capabilities and expertise in kinase biology.
ACRS Income Statement
ACRS Balance Sheet
ACRS Price History
ACRS Valuation
ACRS Dividends and Shares
ACRS Corporate Info
Suite 103
Wayne, PA 19087